Ordering Recommendation

Use to detect the 2019 novel coronavirus (SARS-CoV-2).

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation

Saliva: Patients should not eat or drink for 30 minutes prior to providing a saliva sample.


Nasopharyngeal swab, oropharyngeal swab, nasal swab, or saliva.

Specimen Preparation

Nasopharyngeal, oropharyngeal, or nasal swab: Place in viral transport media (ARUP supply #12884) available online through eSupply using ARUP Connect or contact ARUP Client Services at 800-522-2787. Place each specimen in an individually sealed bag.
Saliva: Transport in COVID-19 ARUP Transport Media (ATM) Saliva Collection Tube (ARUP supply #56257) available online through eSupply using ARUP Connect or contact ARUP Client Services at 800-522-2787.

Storage/Transport Temperature


Unacceptable Conditions

Undiluted saliva. Saliva submitted in anything other than the ARUP Saliva Collection Tube. Swabs not in media. Wood swabs, calcium alginate swabs. Specimens in glass tubes.


Specimen source required.


Swabs:  Ambient: 2 days; Refrigerated: 2 days; Frozen: 1 month
Saliva: Ambient: 5 days; Refrigerated: 5 days, Frozen: 5 days


Qualitative Nucleic Acid Amplification (NAA)




1-4 days

Reference Interval

Interpretive Data

This test should be ordered for the detection of the 2019 novel coronavirus SARS-CoV-2 in individuals who meet SARS-CoV-2 clinical and/or epidemiological criteria.

The Coronavirus SARS-CoV-2 (COVID-19) by nucleic acid amplification test is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA) for U.S. laboratories certified under CLIA to perform high complexity tests. This test has not been FDA cleared or approved. In compliance with this authorization, please visit https://www.aruplab.com/infectious-disease/coronavirus for more information and to access the applicable information sheets.

Not Detected results do not rule out the presence of PCR inhibitors in the patient specimen or assay-specific nucleic acid in concentrations below the level of detection by the assay.

Detected results are indicative of the presence of SARS-CoV-2 RNA. Due to the complexity of nucleic acid amplification methodologies, there may be a risk of false-positive results. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.

Reliable results are dependent on adequate specimen collection, transport, storage, and handling.

Compliance Category

Depends on Specimen/Source/Method


Hotline History


CPT Codes



Component Test Code* Component Chart Name LOINC
3002639 SARS-CoV-2 Source 31208-2
3002640 SARS-CoV-2 by NAA 94500-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • 2019-nCoV
  • Coronavirus disease - 2019
  • COVID-19
  • COVID-19 Illness
  • COVID-2019
  • SARS-CoV-2
SARS-CoV-2 (COVID-19) by NAA